5-YEAR RELATIVE SURVIVAL RATE BETWEEN SEMINOMA AND NON-SEMINOMA TESTICULAR CANCER IN SINGLE CENTER

Ben Julian Mantiri, G. P. Siregar, Syah Mirsya
{"title":"5-YEAR RELATIVE SURVIVAL RATE BETWEEN SEMINOMA AND NON-SEMINOMA TESTICULAR CANCER IN SINGLE CENTER","authors":"Ben Julian Mantiri, G. P. Siregar, Syah Mirsya","doi":"10.32421/juri.v30i3.829","DOIUrl":null,"url":null,"abstract":"ABSTRACT \nObjective: This study was conducted to provide data about the survival rate of testicular cancer patients with different histology in the year 2013 – 2017 in Adam Malik General Hospital and to compare these estimates with other studies conducted in another center. Material & Methods: Medical records of testicular cancer patients from 2013 to 2017 in Adam Malik General Hospital were collected. We measured 5-year relative survival between the histology group of seminoma and non-seminoma estimated using Kaplan-Meier survival analysis. Also, using Kaplan-Meier for survival analysis estimated, 5-year relative survival between metastatic and non-metastatic was estimated. Results: 63 male patients (mean age 27.5 ± 17.6 years old) were included in this study. The distribution of histology were non-seminoma (53.9%), seminoma (39.9%), non-Hodgkin lymphoma (4.7%), and gonadoblastoma (1.5%). The 5-year relative survival rate was 82.5% for the seminoma group and 80.9 % for the non-seminoma group. The 5-year survival rate in the seminoma group with metastatic was 77.8% and in the non-metastatic group was 87.3 %. The 5-year survival rate in the non-seminoma group with metastatic was 74.6 % and in the non-metastatic group was 88.9 %. Conclusion: 5-year relative survival was better for the seminoma group than the non-seminoma group. Moreover, non-metastasis seminoma was found to have a better outcome than the metastatic group. Despite that, in the non-metastatic group, it is found that non-seminoma testicular cancer has a better survival rate than seminoma testicular cancer. \nKeywords: 5-year relative survival rate, seminoma, non-seminoma, testicular cancer.","PeriodicalId":13565,"journal":{"name":"Indonesian Journal of Urology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indonesian Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32421/juri.v30i3.829","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

ABSTRACT Objective: This study was conducted to provide data about the survival rate of testicular cancer patients with different histology in the year 2013 – 2017 in Adam Malik General Hospital and to compare these estimates with other studies conducted in another center. Material & Methods: Medical records of testicular cancer patients from 2013 to 2017 in Adam Malik General Hospital were collected. We measured 5-year relative survival between the histology group of seminoma and non-seminoma estimated using Kaplan-Meier survival analysis. Also, using Kaplan-Meier for survival analysis estimated, 5-year relative survival between metastatic and non-metastatic was estimated. Results: 63 male patients (mean age 27.5 ± 17.6 years old) were included in this study. The distribution of histology were non-seminoma (53.9%), seminoma (39.9%), non-Hodgkin lymphoma (4.7%), and gonadoblastoma (1.5%). The 5-year relative survival rate was 82.5% for the seminoma group and 80.9 % for the non-seminoma group. The 5-year survival rate in the seminoma group with metastatic was 77.8% and in the non-metastatic group was 87.3 %. The 5-year survival rate in the non-seminoma group with metastatic was 74.6 % and in the non-metastatic group was 88.9 %. Conclusion: 5-year relative survival was better for the seminoma group than the non-seminoma group. Moreover, non-metastasis seminoma was found to have a better outcome than the metastatic group. Despite that, in the non-metastatic group, it is found that non-seminoma testicular cancer has a better survival rate than seminoma testicular cancer. Keywords: 5-year relative survival rate, seminoma, non-seminoma, testicular cancer.
单中心精原细胞瘤与非精原细胞瘤睾丸癌的5年相对生存率
【摘要】目的:本研究旨在提供2013 - 2017年亚当马利克综合医院不同组织学睾丸癌患者的生存率数据,并与其他中心的研究结果进行比较。材料与方法:收集2013 - 2017年亚当马利克综合医院睾丸癌患者的医疗记录。我们测量了精原细胞瘤和非精原细胞瘤组织学组的5年相对生存率,使用Kaplan-Meier生存分析估计。此外,使用Kaplan-Meier进行生存分析估计,估计转移性和非转移性之间的5年相对生存率。结果:共纳入63例男性患者,平均年龄27.5±17.6岁。组织学分布为非精原细胞瘤(53.9%)、精原细胞瘤(39.9%)、非霍奇金淋巴瘤(4.7%)和性腺母细胞瘤(1.5%)。精原细胞瘤组和非精原细胞瘤组的5年相对生存率分别为82.5%和80.9%。转移性精原细胞瘤组5年生存率为77.8%,非转移性精原细胞瘤组5年生存率为87.3%。非精原细胞瘤转移组5年生存率为74.6%,非转移组为88.9%。结论:精原细胞瘤组5年相对生存率高于非精原细胞瘤组。此外,非转移性精原细胞瘤的预后优于转移性精原细胞瘤。尽管如此,在非转移组中,发现非精原细胞瘤睾丸癌的生存率高于精原细胞瘤睾丸癌。关键词:5年相对生存率,精原细胞瘤,非精原细胞瘤,睾丸癌
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信